FY2025 Earnings Forecast for AVDL Issued By Leerink Partnrs

Avadel Pharmaceuticals plc (NASDAQ:AVDL) – Equities research analysts at Leerink Partnrs decreased their FY2025 earnings per share (EPS) estimates for Avadel Pharmaceuticals in a research report issued to clients and investors on Tuesday, November 12th. Leerink Partnrs analyst M. Goodman now forecasts that the company will earn $0.95 per share for the year, down from their prior forecast of $1.05. The consensus estimate for Avadel Pharmaceuticals’ current full-year earnings is ($0.50) per share. Leerink Partnrs also issued estimates for Avadel Pharmaceuticals’ FY2026 earnings at $2.00 EPS and FY2028 earnings at $3.15 EPS.

Avadel Pharmaceuticals (NASDAQ:AVDL) last issued its earnings results on Tuesday, November 12th. The company reported ($0.03) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.06) by $0.03. Avadel Pharmaceuticals had a negative return on equity of 93.34% and a negative net margin of 52.53%. The company had revenue of $50.00 million during the quarter, compared to analysts’ expectations of $48.43 million. During the same period in the prior year, the business earned ($0.41) EPS. The firm’s quarterly revenue was up 624.6% on a year-over-year basis.

Several other research firms have also weighed in on AVDL. Needham & Company LLC reiterated a “buy” rating and issued a $22.00 target price on shares of Avadel Pharmaceuticals in a report on Tuesday. Oppenheimer lifted their price target on shares of Avadel Pharmaceuticals from $29.00 to $30.00 and gave the company an “outperform” rating in a research report on Thursday, October 31st. Finally, HC Wainwright lowered their price objective on Avadel Pharmaceuticals from $27.00 to $25.00 and set a “buy” rating for the company in a research report on Wednesday. Seven research analysts have rated the stock with a buy rating, According to MarketBeat.com, Avadel Pharmaceuticals has an average rating of “Buy” and an average target price of $24.43.

Avadel Pharmaceuticals Trading Down 5.9 %

Shares of AVDL stock opened at $10.91 on Thursday. Avadel Pharmaceuticals has a twelve month low of $10.39 and a twelve month high of $19.09. The company’s 50-day moving average price is $13.49 and its 200-day moving average price is $15.02. The stock has a market cap of $1.05 billion, a price-to-earnings ratio of -13.81 and a beta of 1.47.

Hedge Funds Weigh In On Avadel Pharmaceuticals

Several large investors have recently made changes to their positions in AVDL. BNP Paribas Financial Markets increased its holdings in Avadel Pharmaceuticals by 60.5% in the 1st quarter. BNP Paribas Financial Markets now owns 4,469 shares of the company’s stock valued at $75,000 after purchasing an additional 1,685 shares during the last quarter. Quantbot Technologies LP purchased a new position in shares of Avadel Pharmaceuticals during the first quarter worth $353,000. Russell Investments Group Ltd. acquired a new stake in shares of Avadel Pharmaceuticals in the first quarter valued at $1,943,000. Avantax Advisory Services Inc. raised its holdings in shares of Avadel Pharmaceuticals by 123.9% in the 1st quarter. Avantax Advisory Services Inc. now owns 55,756 shares of the company’s stock valued at $942,000 after buying an additional 30,856 shares during the period. Finally, Lord Abbett & CO. LLC acquired a new position in Avadel Pharmaceuticals during the 1st quarter worth about $3,264,000. 69.19% of the stock is currently owned by institutional investors and hedge funds.

Avadel Pharmaceuticals Company Profile

Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017.